- Home
- OKUR vs BYSI Comparison
OKUR vs BYSI Comparison
Compare OKUR & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- BYSI
- Stock Information
- Founded
- OKUR 2011
- BYSI 2010
- Country
- OKUR United States
- BYSI United States
- Employees
- OKUR N/A
- BYSI N/A
- Industry
- OKUR
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- BYSI Health Care
- Exchange
- OKUR NYSE
- BYSI Nasdaq
- Market Cap
- OKUR 75.5M
- BYSI 72.1M
- IPO Year
- OKUR N/A
- BYSI 2017
- Fundamental
- Price
- OKUR $5.74
- BYSI $1.74
- Analyst Decision
- OKUR Strong Buy
- BYSI
- Analyst Count
- OKUR 4
- BYSI 0
- Target Price
- OKUR $35.00
- BYSI N/A
- AVG Volume (30 Days)
- OKUR 135.4K
- BYSI 14.4K
- Earning Date
- OKUR 02-14-2025
- BYSI 01-01-0001
- Dividend Yield
- OKUR N/A
- BYSI N/A
- EPS Growth
- OKUR N/A
- BYSI N/A
- EPS
- OKUR N/A
- BYSI N/A
- Revenue
- OKUR N/A
- BYSI $1,876,000.00
- Revenue This Year
- OKUR N/A
- BYSI N/A
- Revenue Next Year
- OKUR N/A
- BYSI N/A
- P/E Ratio
- OKUR N/A
- BYSI N/A
- Revenue Growth
- OKUR N/A
- BYSI 21.03
- 52 Week Low
- OKUR $4.58
- BYSI $0.99
- 52 Week High
- OKUR $20.00
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- BYSI 55.08
- Support Level
- OKUR N/A
- BYSI $1.66
- Resistance Level
- OKUR N/A
- BYSI $1.80
- Average True Range (ATR)
- OKUR 0.00
- BYSI 0.07
- MACD
- OKUR 0.00
- BYSI 0.01
- Stochastic Oscillator
- OKUR 0.00
- BYSI 63.93
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.